Robert A. Lafyatis, MD
Adjunct Professor
Boston University Chobanian & Avedisian School of Medicine

MD, University of Cincinnati
BS, Massachusetts Institute of Technology

Dr. Lafyatis carries out patient oriented research into the cause and treatment of systemic sclerosis. This includes early phase clinical trials into new therapeutic agents in patients with systemic sclerosis. He has been investigating the mechanisms of actions and markers of response for novel therapeutics, such as the B cell depleting agent, rituximab and the immunosuppressant agent, mycophenlate. Additional studies are aimed at identifying biomarkers in systemic sclerosis using microarray gene expression analysis of skin and blood in scleroderma patients. Ongoing biomarker studies include investigation into molecular markers of pulmonary hypertension in systemic sclerosis. Dr. Lafyatis also carries out basic research into the cause of fibrosis and vasculopathy in systemic sclerosis using patient samples and murine disease models. His studies have provided key insights into one widely used model of systemic sclerosis, the tight skin mouse. His studies are currently focused on understanding how autoimmunity and the innate immune system lead to fibrosis and vascular damage. This has recently led to the discovery of increased interferon-regulated gene expression in white blood cells of patients with systemic sclerosis. Ongoing research is aimed at better understanding the cause of altered gene expression by monocytes and other cells in the innate immune system.

Boston University
Evans Center for Interdisciplinary Biomedical Research

A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
12/01/2015 - 11/30/2021 (Co-Investigator)
PI: Robert W. Simms, MD
Corbus Pharmaceuticals Holdings, Inc.

A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy volunteers and Subjects with Systemic Lupus Erythematosus
04/09/2015 - 04/08/2020 (Co-Investigator)
PI: Christina Lam, MD
Biogen Idec

Scleroderma Clinical Repository (SCaR)
10/01/2014 - 09/30/2019 (PI)
Regeneron Pharmaceuticals, Inc.

ASSET: A Phase II study to evaluate subcutaneous abatacept vs. placebo in diffuse cutaneous systemic sclerosis - a double-blind, placebo-controlled, randomized controlled trial [IMI101-344]
03/31/2015 - 06/30/2019 (Subcontract PI)
Regents of the University of Michigan Bristol-Myers Squibb

Randomized, double-blind, placebo-controlled trial of IL1-Trap, Rilonacept, in Systemic Sclerosis-A Phase I/II Biomarker Trial
12/01/2011 - 02/05/2019 (PI)
Regeneron Pharmaceuticals, Inc.

Scleroderma Workshop
02/01/2010 - 01/31/2018 (PI)
MedImmune, Inc.

Nox4 Inhibitor in Systemic Sclerosis
11/14/2014 - 11/13/2017 (PI)
Mistral Therapeutics, Inc.

09/01/2011 - 08/31/2017 (PI of Sub-Project / SP)
PI: Robert W. Simms, MD
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases

Rheumatic Diseases Research Core Centers
09/01/2011 - 08/31/2017 (PI of Sub-Project / SP)
PI: Robert W. Simms, MD
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases

A Randomized, Double-Blind, Placebo-Controlled Trial of Topical C-82 in Systemic Sclerosis-A Phase I/II Biomarker and Safety Trial
04/02/2015 - 04/01/2017 (PI)
PRISM Pharma Co Ltd

Showing 10 of 42 results. Show All Results


Yr Title Project-Sub Proj Pubs
2023 Administrative Core 5P50AR080612-02-9032
2023 Cell epigenetics & communication in systemic sclerosis and localized scleroderma skin disease 5P50AR080612-02-9847
2023 Clinical-Translational Studies in Skin, Lung, and Vascular Complications in Systemic Sclerosis 5P50AR080612-02
2022 Clinical-Translational Studies in Skin, Lung, and Vascular Complications in Systemic Sclerosis 1P50AR080612-01
2022 Cell epigenetics & communication in systemic sclerosis and localized scleroderma skin disease 1P50AR080612-01-9847
2022 Administrative Core 1P50AR080612-01-9844
2022 Mapping Age-Related Changes in the Lung 5U01HL145550-04
2021 Mapping Age-Related Changes in the Lung 7U01HL145550-03
2021 Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis 5P50AR060780-10 80
2021 Project 1: Systemic Sclerosis Skin Biomarkers & Therapeutics 5P50AR060780-10-6918 80
Showing 10 of 77 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Harvey LD, Alotaibi M, Kim HJ, Tai YY, Tang Y, Sun W, El Khoury W, Woodcock CC, Aaraj YA, St Croix CM, Stolz DB, Lee J, Cheng MH, Schwantes-An TH, Desai AA, Pauciulo MW, Nichols WC, Webb A, Lafyatis R, Nouraie M, Wu H, McDonald JG, Chauvet C, Cheng S, Bahar I, Bertero T, Benza RL, Jain M, Chan SY. Genetic regulation and targeted reversal of lysosomal dysfunction and inflammatory sterol metabolism in pulmonary arterial hypertension. bioRxiv. 2024 Mar 01. PMID: 38464060; PMCID: PMC10925169; DOI: 10.1101/2024.02.26.582142;
  2. Padilla CM, Valenzi E, Tabib T, Nazari B, Sembrat J, Rojas M, Fuschiotti P, Lafyatis R. Increased CD8+ tissue resident memory T cells, regulatory T cells and activated natural killer cells in systemic sclerosis lungs. Rheumatology (Oxford). 2024 Mar 01; 63(3):837-845. PMID: 37310903; PMCID: PMC10907815; DOI: 10.1093/rheumatology/kead273;
  3. Rahimikollu J, Xiao H, Rosengart A, Rosen ABI, Tabib T, Zdinak PM, He K, Bing X, Bunea F, Wegkamp M, Poholek AC, Joglekar AV, Lafyatis RA, Das J. SLIDE: Significant Latent Factor Interaction Discovery and Exploration across biological domains. Nat Methods. 2024 May; 21(5):835-845. PMID: 38374265
  4. Tirelli F, Pachera E, Gmür S, Lafyatis R, Huang M, Zulian F, Camarillo Retamosa E, Kania G, Distler O. Long non-coding RNA H19X as a regulator of mononuclear cell adhesion to the endothelium in systemic sclerosis. Rheumatology (Oxford). 2024 Feb 01. PMID: 38305495
  5. Bahudhanapati H, Tan J, Apel RM, Seeliger B, Schupp J, Li X, Sullivan DI, Sembrat J, Rojas M, Tabib T, Valenzi E, Lafyatis R, Mitash N, Hernandez Pineda R, Jawale C, Peroumal D, Biswas P, Tedrow J, Adams T, Kaminski N, Wuyts WA, McDyer JF, Gibson KF, Alder JK, Königshoff M, Zhang Y, Nouraie M, Prasse A, Kass DJ. Increased expression of CXCL6 in secretory cells drives fibroblast collagen synthesis and is associated with increased mortality in idiopathic pulmonary fibrosis. Eur Respir J. 2024 Jan; 63(1).View Related Profiles. PMID: 37918852
  6. Ma F, Tsou PS, Gharaee-Kermani M, Plazyo O, Xing X, Kirma J, Wasikowski R, Hile GA, Harms PW, Jiang Y, Xing E, Nakamura M, Ochocki D, Brodie WD, Pillai S, Maverakis E, Pellegrini M, Modlin RL, Varga J, Tsoi LC, Lafyatis R, Kahlenberg JM, Billi AC, Khanna D, Gudjonsson JE. Systems-based identification of the Hippo pathway for promoting fibrotic mesenchymal differentiation in systemic sclerosis. Nat Commun. 2024 Jan 03; 15(1):210. PMID: 38172207; PMCID: PMC10764940; DOI: 10.1038/s41467-023-44645-6;
  7. Zhu H, Luo H, Skaug B, Tabib T, Li YN, Tao Y, Matei AE, Lyons MA, Schett G, Lafyatis R, Assassi S, Distler JHW. Fibroblast Subpopulations in Systemic Sclerosis: Functional Implications of Individual Subpopulations and Correlations with Clinical Features. J Invest Dermatol. 2023 Dec 24. PMID: 38147960
  8. Jia M, Sayed K, Kapetanaki MG, Dion W, Rosas L, Irfan S, Valenzi E, Mora AL, Lafyatis RA, Rojas M, Zhu B, Benos PV. LEF1 isoforms regulate cellular senescence and aging. Aging Cell. 2023 Dec; 22(12):e14024. PMID: 37961030; PMCID: PMC10726832; DOI: 10.1111/acel.14024;
  9. Gaydosik AM, Stonesifer CJ, Tabib T, Lafyatis R, Geskin LJ, Fuschiotti P. The mycosis fungoides cutaneous microenvironment shapes dysfunctional cell trafficking, antitumor immunity, matrix interactions, and angiogenesis. JCI Insight. 2023 Oct 09; 8(19). PMID: 37669110; PMCID: PMC10619438; DOI: 10.1172/jci.insight.170015;
  10. Cruz T, Agudelo Garcia PA, Chamucero-Millares JA, Bondonese A, Mitash N, Sembrat J, Tabib T, Zhang W, Seyed N, Peters V, Stacey S, Vignali D, Mora AL, Lafyatis R, Rojas M. End-Stage Idiopathic Pulmonary Fibrosis Lung Microenvironment Promotes Impaired NK Activity. J Immunol. 2023 Oct 01; 211(7):1073-1081. PMID: 37566492
Showing 10 of 251 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 251 publications over 35 distinct years, with a maximum of 19 publications in 2023


Contact for Mentoring:

75 E. Newton St Evans Building
Boston MA 02118
Google Map

Lafyatis's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department